Citations

Clear

125 citation(s) found for "Tyson, MD".

Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement
Oyer, Randall A. , Hurley, Patricia A. , Boehmer, Leigh , Bruinooge, Suanna S. , Levit, Kathryn , Barrett, Nadine J. , Benson, Al B. , Bernick, Lea Ann, Byatt, Leslie, Charlot, Marjory , Crews, Jennie R. , DeLeon, Kyle, Green, Sybil, Guerra, Carmen E. , Hamroun, Leila, Hardy, Claudia M. , Hempstead, Bridgette, Jeames, Sanford , Mann, Mel , Matin, Khalid , McCaskill‐Stevens, Worta , Merrill, Janette K. , Nowakowski, Grzegorz S. , Patel, Manali I. , Pressman, Alice , Segura, Juanita, Segarra-Vasquez, Barbara, Williams, Jen Hanley, Williams, J.E. Caerwyn , Winkfield, Karen M. , Yang, Eddy S. , Zwicker, Victoria, Pierce, Lori J. , Hurley, Patricia , Bruinooge, Suanna Steeby , Barrett, Nadine , Benson, Al , Fashoyin-Aje, Lola , Garrett-Mayer, Elizabeth , Gralow, Julie R , Guerra, Carmen E , Jeames, Sanford , Mann, Mel , Merrill, Janette , Nowakowski, Grzegorz S , Patel, Manali I , Pressman, Alice , Ramirez, Amelie G , Hanley Williams, Jen , Williams, James E , Winkfield, Karen M , Yang, Eddy S , Pierce, Lori J , Charlot, Marjory , Oyer, Randall A , Garrett‐Mayer, Elizabeth , Gralow, Julie R. , Segarra-Vasquez, Barbara

Mayo Clinic

Journal of Clinical Oncology | May 19, 2022 | Volume: 40 | Issue: 19 | Pages: 2163-2171

10.1200/jco.22.00754 | PMID 35588469 Get It

A concerted commitment across research stakeholders is necessary to increase equity, diversity, and inclusion (EDI) and address barriers to cancer clinical trial recruitment and participation. Racial and ethnic diversity among trial participants is key to understanding intrinsic and extrinsic factors that may affect patient response to cancer treatments. This ASCO and Association of Community Cancer Centers (ACCC) Research Statement presents specific recommendations and strategies for the research community to improve EDI in cancer clinical trials. There are six overarching recommendations: (1) clinical trials are an integral component of high-quality cancer care, and every person with cancer should have the opportunity to participate; (2) trial sponsors and investigators should design and implement trials with a focus on reducing barriers and enhancing EDI, and work with sites to conduct trials in ways that increase participation of under-represented populations; (3) trial sponsors, researchers, and sites should form long-standing partnerships with patients, patient advocacy groups, and community leaders and groups; (4) anyone designing or conducting trials should complete recurring education, training, and evaluation to demonstrate and maintain cross-cultural competencies, mitigation of bias, effective communication, and a commitment to achieving EDI; (5) research stakeholders should invest in programs and policies that increase EDI in trials and in the research workforce; and (6) research stakeholders should collect and publish aggregate data on racial and ethnic diversity of trial participants when reporting results of trials, programs, and interventions to increase EDI. The recommendations are intended to serve as a guide for the research community to improve participation rates among people from racial and ethnic minority populations historically under-represented in cancer clinical trials. ASCO and ACCC will work at all levels to advance the recommendations in this publication.
Patient Engagement in Urological Research: A Call to Action
Tyson, Mark D. , Siemens, D. Robert

Mayo Clinic

Journal of Urology | May 10, 2022 | Volume: 208 | Issue: 2 | Pages: 241-242

10.1097/ju.0000000000002762 | PMID 35536672 Get It

A phase 3, single-arm study of CG0070 in subjects with nonmuscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).
Uchio, Edward , Lamm, Donald L. , Tyson, Mark D. , Tran, Ben, Anderson, Paul , Grandi, Paola , Shore, Neal D. , Kamat, Ashish M. , Grandi, Paola, Burke, James M.

Mayo Clinic

Journal of Clinical Oncology | February 16, 2022 | Volume: 40 | Issue: 6_suppl | Pages: TPS598-TPS598

10.1200/jco.2022.40.6_suppl.tps598 Get It

TPS598 Background: CG0070 is a serotype 5 adenovirus engineered to express GM-CSF and replicate in cells with mutated or deficient RB, with response rates (RR) of approximately 45% observed in patients with recurrent NMIBC after BCG (J Urol. 2012;188:2391–7; Urol Oncol. 2018;36(10):440–7). This single arm phase 3 study (NCT04452591) was launched to confirm the clinical activity of CG0070 in patients with BCG Unresponsive NMIBC. Methods: 110 patients with BCG-unresponsive CIS with or without concurrent Ta or T1 disease will be treated with intravesical (IVe) CG0070 at a dose of 1x1012 vp. CG0070 will be administered as follows: induction weekly x 6 followed by weekly x 3 maintenance instillations at months 3, 6, 9, 12, and 18. Patients with persistent CIS or HG Ta at 3 months (m) may receive re-induction with weekly x 6 CG0070. Assessment of response will include q 3 m cystoscopy with biopsy of areas suspicious for disease, urine cytology, CTU/MRU, and mandatory bladder mapping at 12 m. Detection of high grade disease within the bladder will be enumerated as recurrence or non-response. The primary endpoint of the study is CR at any time on study as assessed by biopsy (directed to cystoscopic abnormalities and mandatory mapping at 12 m), urine cytology, and radiography, as above. Secondary endpoints include CR at 12 m, duration of response, progression free survival, cystectomy free survival and safety. Correlative assessments include changes in the tumor immune microenvironment, systemic immune induction as reflected in the peripheral blood and urine, as well as viral replication and transgene expression. Baseline expression of coxsackie adenovirus receptor, E2F transcription factor as well as anti-adenovirus antibody titer will be correlated with tumor response. Study enrollment globally is ongoing including in North America, Taiwan, Japan, and South Korea. Refs. Burke JM, Lamm DL, Meng MV, Nemunaitis JJ, Stephenson JJ, Arseneau JC, Aimi J, Lerner S, Yeung AW, Kazarian T, Maslyar DJ, McKiernan JM. A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. Clinical trial information: NCT04452591.
BCG efficacy in nonmuscle-invasive bladder cancer after prior radiation treatment for prostate cancer.
Durant, Adri , Chang, Yu‐Hui, Tyson, Mark D. , Faraj, Kassem

Mayo Clinic

Journal of Clinical Oncology | February 16, 2022 | Volume: 40 | Issue: 6_suppl | Pages: 482-482

10.1200/jco.2022.40.6_suppl.482 Get It

482 Background: Prostate radiotherapy is associated with worse oncologic outcomes in patients with bladder cancer. This is thought to be secondary to microvascular damage resulting in propagation of inflammation. There is sparse data on the effect of prior radiotherapy on the efficacy of intravesical Bacillus Calmette-Guerin (BCG) in patients with non-muscle invasive bladder cancer (NMIBC). We sought to evaluate BCG response and outcomes in NMIBC patients who have previously undergone prostate radiotherapy compared to patients with no prior history of pelvic radiotherapy. Methods: This is a retrospective cohort study that includes patients who received intravesical BCG for NMIBC at our institution from 2001 to 2019. Data were collected on patient and pathologic characteristics. Patients were stratified into three cohorts: prior radiotherapy (RT), radical prostatectomy (RP), and no prostate cancer (No PCa). Wilcoxon rank sum test and Chi-squared test were used for comparison between groups. The primary endpoints included recurrence at one-year, progression to MIBC and progression to metastatic disease. Results: In 199 total patients who underwent BCG for NMIBC, 23 had a prior history of radiotherapy treatment for prostate cancer, while 17 underwent prior radical prostatectomy. Overall, 41.2% of patients had recurrence at one year. There was no difference in recurrence at one year between the cohorts: 42.8% No PCa, 29.4% RP and 39.1% RT; p = 0.56. There was also no difference in progression to MIBC (6.9% No PCA, 0% RP, and 8.7% RT) or progression to metastatic disease (6.9% No PCA, 5.9% RP and 4.3% RT) with p = 0.50 and 0.89 respectively. Conclusions: The efficacy of intravesical BCG does not appear to be modified by prior radiation treatment for prostate cancer in patients with NMIBC.[Table: see text]
Utility of Blue Light Cystoscopy for Post-bacillus Calmette-Guérin Bladder Cancer Recurrence Detection: Implications for Clinical Trial Recruitment and Study Comparisons
Chappidi, Meera R. , Meng, Maxwell V. , Bivalacqua, Trinity J. , Holzbeierlein, Jeffrey M., Kaimakliotis, Hristos Z. , Konety, Badrinath R. , Liao, Joseph C. , Pohar, Kamal S. , Taylor, Jennifer M. , Tyson, Mark D. , Willard, Brian, Porten, Sima P. , Kates, Max , Yang, Heiko , Daneshmand, Siamak , Steinberg, Gary D. , Lotan, Yair

Mayo Clinic

Journal of Urology | October 25, 2021 | Volume: 207 | Issue: 3 | Pages: 534-540

10.1097/ju.0000000000002308 | PMID 34694916 Get It

Role of blue‐light cystoscopy in detecting invasive bladder tumours: data from a multi‐institutional registry
Ahmadi, Hamed , Ladi‐Seyedian, Seyedeh‐Sanam , Konety, Badrinath R. , Pohar, Kamal S. , Holzbeierlein, Jeffrey M., Kates, Max , Willard, Brian, Taylor, Jennifer M. , Kaimakliotis, Hristos Z. , Porten, Sima P. , Tyson, Mark D. , Group, the Blue Light Cystoscopy with Cysview Registry, Lotan, Yair , Daneshmand, Siamak , Liao, Joseph C. , Steinberg, Gary D. , Lotan, Yair , Daneshmand, Siamak , Group, the Blue Light Cystoscopy with Cysview Registry

Mayo Clinic

BJU International | October 13, 2021 | Volume: 130 | Issue: 1 | Pages: 62-67

10.1111/bju.15614 | PMID 34637596 Get It

Objectives To evaluate the role of blue‐light cystoscopy (BLC) in detecting invasive tumours that were not visible on white‐light cystoscopy (WLC). Patients and Methods Using the multi‐institutional Cysview registry database, patients who had at least one white‐light negative (WL–)/blue‐light positive (BL+) lesion with invasive pathology (≥T1) as highest stage tumour were identified. All WL–/BL+ lesions and all invasive tumours in the database were used as denominators. Relevant baseline and outcome data were collected. Results Of the 3514 lesions (1257 unique patients), 818 (23.2%) lesions were WL−/BL+, of those, 55 (7%) lesions were invasive (48 T1, seven T2; 47 unique patients) including 28/55 (51%) de novo invasive lesions (26 unique patients). In all, 21/47 (45%) patients had WL−/BL+ concommitant carcinoma in situ and/or another T1 lesions. Of 22 patients with a WL−/BL+ lesion who underwent radical cystectomy (RC), high‐risk pathological features leading to RC was only visible on BLC in 18 (82%) patients. At time of RC, 11/22 (50%) patients had pathological upstaging including four (18%) with node‐positive disease. Conclusions A considerable proportion of invasive lesions are only detectable by BLC and the rate of pathological upstaging is significant. Our present findings suggest an additional benefit of BLC in the detection of invasive bladder tumours that has implications for treatment approach.
008 Long-term Success with Diminished Opioid Prescribing After Men's Health Urologic Procedures Using Standardized Postoperative Opioid Prescribing Guidelines: An Interrupted Time-Series Analysis
Findlay, B., Britton, Cameron J. , Glasgow, Amy E. , Gettman, Matthew T., Tyson, Mark D. , Pak, Raymond , Ziegelmann, M., Findlay, B., Viers, Boyd R. , Habermann, Elizabeth B.

Mayo Clinic

The Journal of Sexual Medicine | March 18, 2021 | Volume: 18 | Issue: Supplement_1 | Pages: S4-S4

10.1016/j.jsxm.2021.01.078 Get It

Effect of intracorporeal urinary diversion on the incidence of benign ureteroenteric stricture after cystectomy
Faraj, Kassem , Navaratnam, Anojan , Abdul-Muhsin, Haidar , Eversman, Sarah, Singh, Vijay Kumar , Tyson, Mark D. , Faraj, Kassem S , Rose, Kyle M., Navaratnam, Anojan K, Abdul-Muhsin, Haidar M , Singh, Vijay , Rose, Kyle

Mayo Clinic

International Journal of Urology | February 20, 2021 | Volume: 28 | Issue: 5 | Pages: 593-597

10.1111/iju.14521 | PMID 33594730 Get It

ObjectivesTo compare ureteroenteric stricture rates after radical cystectomy in patients who undergo an intracorporeal urinary diversion versus other surgical approaches.MethodsWe retrospectively reviewed health records of all patients who underwent cystectomy with urinary diversion at Mayo Clinic Hospital (Phoenix, AZ, USA) from 1 January 2007 through 1 January 2018. Ureteroenteric stricture was identified by surveillance imaging. Patients were stratified by surgical approach: open radical cystectomy, robot‐assisted radical cystectomy with extracorporeal urinary diversion and robot‐assisted radical cystectomy‐intracorporeal urinary diversion. A Cox proportional hazards model was fitted that included independent predictors of stricture development.ResultsOf the 573 cystectomies assessed, 236 (41.2%) were carried out robotically. In the robot‐assisted radical cystectomy cohort, 39 patients (16.5%) underwent intracorporeal urinary diversion. The median follow‐up period was 55, 70 and 71 months for the open radical cystectomy, robot‐assisted radical cystectomy‐extracorporeal urinary diversion and robot‐assisted radical cystectomy‐intracorporeal urinary diversion groups, respectively. Subgroup stricture rates were as follows: open radical cystectomy, 8.0%; robot‐assisted radical cystectomy‐extracorporeal urinary diversion, 9.6%; and robot‐assisted radical cystectomy‐intracorporeal urinary diversion, 2.6% (P = 0.33). The median time to stricture was 5 months (interquartile range 3.3–11.5 months). In the bivariable analysis, factors that were associated with the development of ureteroenteric stricture were postoperative urinary leak (hazard ratio 3.177, 95% confidence interval 1.129–8.935; P = 0.03) and body mass index (hazard ratio 1.078, 95% confidence interval 1.027–1.132; P = 0.002). On multivariable logistic regression analysis, intracorporeal urinary diversion approach was not associated with the development of ureteroenteric stricture (hazard ratio 0.272, 95% confidence interval 0.036–2.066; P = 0.21).ConclusionsUreteroenteric stricture is a complication that typically occurs within the first postoperative year. Although our results did not support major differences in outcomes between intracorporeal urinary diversion and extracorporeal urinary diversion, the small sample size did not exclude the possibility of a type 2 statistical error.
Declining Medicare Reimbursement for Urologists: An Opportunity for Informed Advocacy
Edmonds, Victoria S. , Haglin, Jack M. , Tyson, Mark D.

Mayo Clinic

Journal of Urology | February 3, 2021 | Volume: 206 | Issue: 1 | Pages: 10-12

10.1097/ju.0000000000001655 | PMID 33533637 Get It